GlassScriptPhysician profile
Leslie A Cotto
NPI 1609167659
$17,087.21
in general payments reported to CMS, 2019-2025
61 companies · $3,085 in 2025
The $3,085 reported for 2025 was more than what 83% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,481 · 2020: $2,079 · 2021: $2,165 · 2022: $2,599 · 2023: $2,810 · 2024: $2,868 · 2025: $3,085.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,763.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $1,946.88 | 2019-2025 | |
| Lilly USA, LLC | $1,863.14 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,849.50 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,346.87 | 2019-2025 | Repatha, Evenity, Prolia |
| Mannkind Corporation | $1,116.05 | 2019-2025 | Afrezza |
| Dexcom, INC. | $620.23 | 2023-2025 | Dexcom G6 Transmitter, Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Bayer Healthcare Pharmaceuticals INC. | $614.47 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $487.21 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Astrazeneca Pharmaceuticals LP | $459.67 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $430.58 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Corcept Therapeutics | $416.18 | 2019-2025 | Korlym |
| Amneal Pharmaceuticals LLC | $398.66 | 2019-2025 | Unithroid |
| Antares Pharma, INC. | $382.34 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Abbott Laboratories | $376.17 | 2021-2025 | Freestyle Libre 3 |
| Tandem Diabetes Care, INC. | $367.22 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $327.35 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Abbvie INC. | $322.43 | 2019-2025 | Synthroid |
| Radius Health, INC. | $309.91 | 2020-2024 | Tymlos |
| Insulet Corporation | $299.34 | 2019-2025 | Omnipod |
| Sequel Med Tech, LLC | $257.08 | 2025 | Twiist |
| Horizon Therapeutics Plc | $249.31 | 2021-2022 | |
| Recordati_rare_diseases_inc. | $225.30 | 2022-2025 | Isturisa, Signifor Lar |
| Neurocrine Biosciences, INC. | $222.44 | 2024-2025 | |
| Endo Pharmaceuticals INC. | $183.09 | 2020-2023 | Nascobal |
| Amarin Pharma, INC. | $174.45 | 2019-2021 | |
| Alvogen INC | $168.40 | 2022-2025 | Teriparatide |
| Zealand Pharma US, INC. | $124.73 | 2020-2022 | |
| Vivus LLC | $114.09 | 2021-2024 | Pancreaze, Qsymia |
| Pfizer INC. | $111.71 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $105.93 | 2019-2021 | |
| Lifescan, INC. | $94.75 | 2019-2022 | |
| Ibsa Pharma INC. | $93.74 | 2020-2025 | Tirosint, Licart, Flector |
| Valeritas, INC. | $86.47 | 2019 | |
| Ascendis Pharma Endocrinology INC | $75.49 | 2023-2025 | Yorvipath |
| Medtronic, INC. | $69.55 | 2021-2025 | Minimed 780g |
| Kyowa Kirin, INC. | $66.44 | 2023-2024 | Crysvita |
| Novartis Pharmaceuticals Corporation | $58.69 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $53.85 | 2024 | Strensiq |
| Madrigal Pharmaceuticals | $52.58 | 2025 | Rezdiffra |
| Esperion Therapeutics, INC. | $47.89 | 2020-2024 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.29 | 2019 | |
| Medtronic Minimed, INC. | $39.62 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $39.28 | 2020-2021 | |
| Ipsen Biopharmaceuticals, INC | $35.62 | 2023 | Somatuline Depot |
| Halozyme INC | $35.35 | 2023 | |
| Acella Pharmaceuticals, LLC | $30.47 | 2024-2025 | NP Thyroid 60 |
| Cequr Corporation | $27.28 | 2024-2025 | Cequr Simplicity |
| Verity Pharmaceuticals INC. | $24.52 | 2025 | Tlando |
| Ultragenyx Pharmaceutical INC. | $23.05 | 2023 | Crysvita |
| Eusa Pharma (US) LLC | $20.96 | 2022 | |
| Companion Medical, INC. | $20.60 | 2020 | |
| Nalpropion Pharmaceuticals LLC | $20.33 | 2019 | |
| Alfasigma USA, INC. | $20.03 | 2021 | |
| Amryt Pharma Holdings LTD | $19.63 | 2022 | |
| Grt US Holding, INC. | $19.20 | 2021 | |
| Globus Medical, INC. | $19.05 | 2025 | Senza |
| Azurity Pharmaceuticals, INC. | $18.90 | 2023 | Adthyza |
| Janssen Pharmaceuticals, INC | $17.69 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $17.68 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $14.24 | 2019 | |
| Cardiovascular Systems INC. | $11.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Cotto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.